RxDoctor Payments Data

Rodney Prater

Psychiatric/Mental Health · Corpus Christi, TXNPI 1477838944

Payments from drug & device makers

$2,709in general payments, 2019–2025

Across 135 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$379
  • Teva Pharmaceuticals USA, Inc.$347
  • Sunovion Pharmaceuticals Inc.$344
  • Otsuka America Pharmaceutical, Inc.$295
  • AbbVie$257
  • Alkermes, Inc.$162
  • plus $925 from 11 others

What the payments were for

  • Food & beverage$2,55294%
  • Education$1566%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,709 in reported general payments places this provider in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$26,480
Medicare patients
72
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate13$28,271
SuboxoneBuprenorphine Hcl/Naloxone Hcl33$15,779
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl32$2,110
Bupropion XlBupropion Hcl76$2,104
Divalproex Sodium30$930
Duloxetine Hcl54$875
Memantine Hcl18$833
Aripiprazole24$828
Quetiapine Fumarate58$812
Buspirone Hcl75$771
Escitalopram Oxalate92$634
Donepezil Hcl59$624
Alprazolam117$616
Trazodone Hcl83$600
Sertraline Hcl47$421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$156$28,27113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →